Urgent.News

One page, thousands of outlets. See who else covered it.

Editions

Business

BioMarin is acquiring Alesta Therapeutics for $275 million to develop a first oral rare bone disease treatment

The deal gives BioMarin access to ALE1, a small-molecule drug in early-stage trials that could become the first oral therapy for hypophosphatasia

BioMarin is acquiring Alesta Therapeutics for $275 million to develop a first oral rare bone disease treatment

We haven't written up this one. Quartz has the full story — the link below goes straight to it.

Read the original at qz.com →

More in Business

More from Wednesday 19 August →